In the BioHarmony Drug Report Database
Basiliximab
Simulect (basiliximab) is an antibody pharmaceutical. Basiliximab was first approved as Simulect on 1998-05-12. It has been approved in Europe to treat graft rejection and kidney transplantation. It is known to target interleukin-2 receptor subunit alpha.
Trade Name
|
Simulect |
|---|---|
Common Name
|
basiliximab |
ChEMBL ID
|
CHEMBL1201439 |
Indication
|
graft rejection, kidney transplantation |
Drug Class
|
Monoclonal antibodies: chimeric, immunomodulating |
Image (chem structure or protein)
